Literature DB >> 10568615

Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.

P E Fine1, I A Carneiro.   

Abstract

The global poliomyelitis eradication initiative has been a tremendous success, with current evidence suggesting that wild poliovirus will cease to circulate anywhere in the world soon after the year 2000. As the goal of wild poliovirus eradication is approached, concern has been raised about the potential for persistent transmission of oral polio vaccine (OPV) viruses, as these viruses are known to revert toward wild-type neurovirulence. This paper has been extracted from a document prepared for the World Health Organization on the implications of OPV transmissibility for the strategy of stopping OPV vaccination after global eradication of wild polioviruses. The authors review the empirical evidence on OPV transmissibility available from household and community transmission studies and from mass-vaccination experiences. They then consider theoretical measures of transmissibility and persistence for wild and OPV viruses (secondary attack rate, basic reproduction number, and critical populations' size), to assess whether transmissibility of OPV viruses is sufficient to allow persistence of these viruses after cessation of vaccination. The findings indicate that OPV viruses could persist under various plausible circumstances, and that this potential should be a major consideration when planning the cessation of OPV vaccination.

Entities:  

Keywords:  Delivery Of Health Care; Diseases; Health; Health Services; Immunization; Organization And Administration; Poliomyelitis--prevention and control; Primary Health Care; Programs; Vaccines; Viral Diseases; World

Mesh:

Substances:

Year:  1999        PMID: 10568615     DOI: 10.1093/oxfordjournals.aje.a009924

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  68 in total

1.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Authors:  Ekaterina A Korotkova; Renee Park; Elena A Cherkasova; Galina Y Lipskaya; Konstantin M Chumakov; Esfir V Feldman; Olen M Kew; Vadim I Agol
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Sociality and health: impacts of sociality on disease susceptibility and transmission in animal and human societies.

Authors:  Peter M Kappeler; Sylvia Cremer; Charles L Nunn
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-05-26       Impact factor: 6.237

5.  A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region.

Authors:  Minetaro Arita; Shuang-Li Zhu; Hiromu Yoshida; Tetsuo Yoneyama; Tatsuo Miyamura; Hiroyuki Shimizu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after Mexican national immunization weeks.

Authors:  Stephanie B Troy; Leticia Ferreyra-Reyes; Chunhong Huang; Clea Sarnquist; Sergio Canizales-Quintero; Christine Nelson; Renata Báez-Saldaña; Marisa Holubar; Elizabeth Ferreira-Guerrero; Lourdes García-García; Yvonne A Maldonado
Journal:  J Infect Dis       Date:  2013-12-23       Impact factor: 5.226

8.  Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China.

Authors:  Dongmei Yan; Yong Zhang; Shuangli Zhu; Na Chen; Xiaolei Li; Dongyan Wang; Xiaozhen Ma; Hui Zhu; Wenbin Tong; Wenbo Xu
Journal:  Clin Vaccine Immunol       Date:  2014-05-21

9.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

10.  Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats.

Authors:  Koen van der Maaden; Sebastiaan J Trietsch; Heleen Kraan; Eleni Maria Varypataki; Stefan Romeijn; Raphäel Zwier; Heiko J van der Linden; Gideon Kersten; Thomas Hankemeier; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.